Hillsdale Investment Management Inc. Grows Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Hillsdale Investment Management Inc. raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 319,800 shares of the biopharmaceutical company’s stock after purchasing an additional 25,500 shares during the period. Hillsdale Investment Management Inc. owned approximately 0.11% of Amicus Therapeutics worth $3,767,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of FOLD. Vanguard Group Inc. increased its holdings in shares of Amicus Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 27,131,873 shares of the biopharmaceutical company’s stock worth $329,924,000 after buying an additional 107,456 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Amicus Therapeutics by 360.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,920 shares of the biopharmaceutical company’s stock worth $481,000 after buying an additional 26,552 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Amicus Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 229,604 shares of the biopharmaceutical company’s stock worth $3,258,000 after buying an additional 19,204 shares during the period. Mutual of America Capital Management LLC increased its holdings in shares of Amicus Therapeutics by 27.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 217,859 shares of the biopharmaceutical company’s stock worth $3,091,000 after buying an additional 46,762 shares during the period. Finally, Vontobel Holding Ltd. purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth about $1,173,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on FOLD. UBS Group reduced their price target on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Morgan Stanley reduced their price target on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, May 10th. Bank of America reduced their price target on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Guggenheim raised Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Tuesday, May 14th. Finally, Wells Fargo & Company assumed coverage on Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Amicus Therapeutics Stock Down 1.0 %

Shares of FOLD traded down $0.10 during mid-day trading on Monday, reaching $10.28. The company had a trading volume of 3,069,428 shares, compared to its average volume of 2,773,343. The company has a debt-to-equity ratio of 2.97, a quick ratio of 2.61 and a current ratio of 3.03. The firm has a 50-day moving average price of $10.02 and a 200 day moving average price of $11.32. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -20.98 and a beta of 0.71.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The firm had revenue of $110.40 million for the quarter, compared to analysts’ expectations of $111.19 million. During the same period in the previous year, the firm posted ($0.18) EPS. The business’s revenue for the quarter was up 27.9% compared to the same quarter last year. On average, sell-side analysts forecast that Amicus Therapeutics, Inc. will post -0.12 EPS for the current year.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total transaction of $75,525.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,928,605.78. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.